Inhibikase Therapeutics (IKT) Net Cash Flow (2020 - 2026)
Inhibikase Therapeutics (IKT) posted Net Cash Flow of -$18.37 million for Q2 2026, compared with $4.3 million a year earlier.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Net Cash Flow (2020 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Net Cash Flow at Inhibikase Therapeutics was -$46.54 million; for FY2025, it came in at $82.73 million, up 74.8% from FY2024.
- Annual Net Cash Flow shows a five-year compound annual growth rate of 42.8% (FY2020 to FY2025).
- In prior years, Inhibikase Therapeutics' Net Cash Flow was $47.33 million in FY2024, $1.98 million in FY2023, -$33.56 million in FY2022 and $26.8 million in FY2021 (+92.3%).
- Quarterly Net Cash Flow has run from a low of -$89.65 million in Q1 2026 to a high of $100.95 million in Q4 2025 over five years.
- According to Business Quant data, Net Cash Flow for the three prior quarters was -$89.65 million (Q1 2026), $100.95 million (Q4 2025) and -$39.47 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | -4.12 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | -3.52 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 4.21 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 2.81 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 9.41 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | -799.00 Mn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 3.26 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 843.00 Mn |
| 10 | Inhibikase Therapeutics | 281.11 Mn | -420.36 Mn | - | 20.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 20.49 Mn |
| Jun 30, 2026 | -18.37 Mn |
| Mar 31, 2026 | -89.65 Mn |
| Dec 31, 2025 | 100.95 Mn |
| Sep 30, 2025 | -39.47 Mn |
| Jun 30, 2025 | 4.30 Mn |
| Mar 31, 2025 | 16.95 Mn |
| Dec 31, 2024 | 55.58 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Jun 30, 2024 | 733,109.00 |
| Mar 31, 2024 | -6.81 Mn |
| Dec 31, 2023 | -5.70 Mn |
| Sep 30, 2023 | 12.96 Mn |
| Jun 30, 2023 | -2.05 Mn |
| Mar 31, 2023 | -3.23 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | -26.43 Mn |
| Jun 30, 2022 | -4.40 Mn |
| Mar 31, 2022 | -4.14 Mn |
| Dec 31, 2021 | -4.10 Mn |
API Access
Inhibikase Therapeutics Net Cash Flow API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-cash-flow&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-cash-flow", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-cash-flow&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();